Research & Education
Health Care Professionals
Patients
 |
|
 |
|
| Through the expertise and compassion of our staff, innovative research, and a multi-disciplinary medical team, the Scott & White Pediatric Hematology/Oncology team delivers high quality cancer care for the children of Central Texas. | |
Pediatric Hematology/Oncology Team
Our goal is to not only cure cancer in children, but to ensure that the physical, developmental and mental well-being of each child is addressed by the team until adulthood. A special team of pediatric specialists tends to these needs, including child-life specialists, nurse practitioners, social workers, psychologists, psychiatrists and physicians. Since children are growing and developing during and after therapy, the team works to ensure that the children will emerge through their treatment on par with their peers.
Services
A full complement of services is available for common and rare childhood cancers and blood disorders, including:
|
|
How to Make Referrals
Referrals from Scott & White physicians, outside physicians, and self-referrals can be made by contacting Pediatric Hematology/Oncology at 254-724-2006.
Once the referred patient is registered into the Scott & White system, a team coordinator will work with both the patient and the referring physician to obtain the medical documents needed for complete review by the Pediatric Hematology/Oncology Team. Additional consults will be scheduled if needed. The team strives to involve the referring physician and primary care physician as integral members of the team.
How the Pediatric Hematology/Oncology Team Works
The Pediatric Hematology/Oncology Team collaborates with the child, and his or her parent(s) or guardian(s) to ensure that each child receives individualized care. Cancer researchers may also be involved if the child is being considered for participation in a clinical trial.
The team coordinator serves as the contact point for patient referrals and makes all appointments needed to diagnose and treat the patient. The coordinator ensures that all aspects of the child's care are coordinated between the relevant medical specialties.
The child's family meets with a financial counselor, giving them the opportunity to ask questions regarding insurance and billing. This initial meeting can help put the family at ease as important decisions are made about the child's care. The counselor is knowledgeable about the financial aspects of cancer care and is a true resource for the family.
The patient visits with a social worker who talks with the child and the family about a range of issues including social services and financial assistance options. The social worker also provides information about cancer support groups and other resources. A Scott & White chaplain is also available for consultation if requested.
The child and family members are encouraged to visit the Center for Cancer Prevention and Care to explore the resources available to them. The center partners with our cancer patients to help address the issues that may occur following a cancer diagnosis by providing resources to the patient and their family. Educational pamphlets, books, videos, and tapes are available at the center and designated computer stations allow patients to access the internet to search cancer information. A caring staff is available to answer questions and locate information for patients. Our educators also provide information on healthy lifestyles, and general chemotherapy teaching. 
The Center for Cancer Prevention and Care also houses Designs of Hope, A Children's Project. This is a project made possible through the creative artwork of the pediatric hematology/oncology children themselves! Drawings and designs by the children are turned into wonderful products such as cards, mugs, T-shirts, magnets, and buttons, which are then sold to the community. Proceeds from the sales are given back to the children in the form of summer camps, picnics, educational software, computers, TVs, VCRs, educational scholarships, and assistance to the families. Both the children and family members enjoy participating in this project, which touches so many lives. More information and a catalog of products is available at the Designs of Hope, A Children's Project website.
Innovative Research in Pediatric Oncology at Scott & White
The Scott & White Cancer Immunotherapy Laboratory is on the forefront of innovative leukemia research. A team of researchers led by Larry Herrera, M.D., is conducting basic and translational research that is examining the safety and efficacy of two novel antibodies in combination for the treatment of relapsed or refractory acute lymphocytic leukemia in children. A phase I study is currently underway for qualifying patients at select institutions around the country.
The results from the research conducted at the Cancer Immunotherapy Laboratory could potentially benefit adult and pediatric cancer patients in the future who have relapsed or refractory leukemia that is no longer responding to chemotherapy. Antibody therapy allows investigators to treat patients with minimal treatment-related toxicity in hopes of targeting and killing cancer cells without significantly harmal normal tissues
Children's Oncology Group (COG) is a National Cancer Institute-sponsored research base that offers dozens of clinical trials for pediatric cancers and blood disorders. As long-standing members with COG, Scott & White is able to offer these trials to qualifying pediatric patients. For more information, contact the Clinical Research Coordinator at 254-724-5079.
Pediatric Cancer Trials
Leukemia and Lymphoma
7944 - A Phase I Study of Combination Therapy with Immunotoxins IMTOX 19+ IMTOX 22 in Children with Refractory/Relapsed CD19+ B-Precursor ALL
AALL0031 - A Children's Oncology Group Pilot Study for the Treatment of Very High Risk Acute Lymphocytic Leukemia in Children and Adolescents
AAML0122 - Phase II Window Evaluation of the Farnesyl Transferase Inhibitor ( R115777) followed by 13-Cis Retinoic Acid, Cytosine Arabinoside and Fludarabine plus Hematopoietic Stem Cell Transplantation in Children with Juvenile Myelomonocytic Leukemia
AAML03P1& - Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy
ACCL01P3 - Differences in Parental Caregiving Demands in Childhood Acute Lymphoblastic Leukemia by Length of Infusion Therapy
A2971 - Treatment of Children with Downs Syndrome (DS) and Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Transient Myeloproliferative Disorder (TMD)
A5971 - Randomized Phase III Study for the Treatment of Newly Diagnosed Disseminated Lymphoblastic Lymphoma or Localized Lymphoblastic Lymphoma
ADVL0023 - A Phase II Study of Docetaxel (Taxotere) (NSC #628503) in Children with Refractory Leukemias
AHOD0031 - A Group-Wide Study of Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents with Newly Diagnosed Intermediate Risk Hodgkin's Disease
AHOD0121 - A Phase II/III STudy of Immunomodulation after High Dose Myeloablative Therapy with Autologous Stem Cell Rescue for Refractory/Relapsed Hodgkin's Disease
ANHL0121 - Combination Chemotherapy and Rituximab in Treating Young Patients with Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
AHOD00P1 - Combination Chemotherapy in Treating Children with Refractory or Relapsed Hodgkin's Lymphoma
POG-9407 - Induction Intensification and Allogeneic Bone Marrow Transplant in Infant Acute Lymphocytic Leukemia: A Children's Oncology Group Pilot Study
COG-C9710- Phase III Randomized Study of Concurrent Tretinoin and Chemotherapy with or without Arsenic Trioxide (NSC #706363) as Initial Consolidation Therapy Followed by Intermittent Tretinoin Maintenance Therapy versus Observation for Patients with Untreated Acute Promyelocytic Leukemia
POG-9904 - ALinC 17: Treatment for Patients with Low Risk Acute Lymphoblastic Leukemia
POG-9905 - ALinC 17: Protocol for Patients with Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia (ALL): A Phase III Study
Neuroblastoma and Gliomas
A3961 - Treatment for Infants and Children with Intermediate Risk Neuroblastoma
ACNS0126 - A Phase II Study of Temozolomide in the Treatment of Children with High-Grade Glioma
ACNS0226 - Tipifarnib in Treating Young Patients with Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma
ANBL0032 - Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma following Myeloablative Therapy and Autologous Stem Cell Rescue
ANBL0321 - A Phase II Study of Fenretinide in Children with Recurrent/Resistant High Risk Neuroblastoma
COG-P9641- Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
P9934 - Systemic Chemotherapy, Second Look Surgery and Conformal Radiation Therapy Limited to the Posterior Fossa and Primary Site for Children >/= 8 months and < 3 years with Non-Metastatic Medulloblastoma: A COG Phase III Study
COG-A9952- Chemotherapy for Progressive Low Grade Astrocytoma in Children Less Than 10 Years Old
99701 - An Intergroup Pilot Study of Concurrent Carboplatin, Vincristine and Radiotherapy Followed by Adjuvant Chemotherapy in Patients with Newly-Diagnosed Central Nervous System Embryonal Tumors
Sarcoma and Solid Tumors
ADVL0122 - A Phase II Trial of Gleevec (imitinib mesylate, formerely STI571) in Children with Refractory or Relapsed Solid Tumors
AEWS0031 - Trial of Chemotherapy Intensification Through Interval Compression in Ewing Sarcoma and Related Tumors
AEWS02B1 - A Group-Wide Biology and Banking Study for Ewing Sarcoma
AEWS0331 - European Ewing Tumor Working Initiative of National Groups Ewing Tumor Studies 1999
AOST0121 - A Group-Wide Phase II Study of Trastuzumab (Herceptin) in Metastatic Osteosarcoma Patients with Tumors that Overexpress HER2
ARST0121 - Randomized Phase II Window Study of Two Different Schedules of Irinotecan in Combination with VCR and Pilot Assessment of Safety and Efficacy of Tirapazamine Combined with Multiagent Chemotherapy for First Relapse or Progressive Disease in Rhabdosarcoma and Related Tumors
POG-9645 - Intergroup Protocol for Treatment of Children with Hepatoblastoma
COG-9761 - Phase II Trial of Irinotecan in Children with Refractory Solid Tumors, A COG Study
COG-D9803 - Randomized Study of Vincristine, Actinomycin-D, and Cyclophosphamide (VAC) versus VAC alternating with Vincristine, Topotecan and Cyclophosphamide for Patients with Intermediate-Risk Rhabdomyosarcoma
9442 - National Wilm's Tumor Late Effects Study
9963 - A Phase II Trial of Rebeccamycin Analogue (NSC #655649) in Children with Solid Tumors
AGCT0132 - Surgery and Combination Chemotherapy in Treating Children with Extracranial Germ Cell Tumors
AEWS02P1 - Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients with Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors
Other
ALTE03N1 - Genetic Study of Late-Occuring Complications In Childhood Cancer Survivors
Back to Top
Bookmark this Page
Print this Page
Resize Text
